<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920500</url>
  </required_header>
  <id_info>
    <org_study_id>HC1702-BE-001</org_study_id>
    <nct_id>NCT04920500</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients</brief_title>
  <official_title>A Randomized, Double-blind, Multiple-Dose, Two-Cycle, Parallel-Group, Bioequivalence Pretrial of Daunorubicin Cytarabine Liposome for Injection in Older, Naive AML Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, Multiple-Dose, Two-Cycle, Parallel-Group, Bioequivalence pretrial&#xD;
      of Daunorubicin Cytarabine liposome for Injection in older, naive patients with Acute Myeloid&#xD;
      Leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bioequivalence Study of Daunorubicin Cytarabine liposome for injection, 100 units (CHINO&#xD;
      Pharmaceutical Group Shijiazhuang Pharmaceutical Co Ltd), versus Vyxeos®, 100 units (Jazz&#xD;
      Pharmaceuticals Public Limited Company), in patients with AML .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics（PK） of Daunorubicin Cytarabine liposomes.</measure>
    <time_frame>up to12 days</time_frame>
    <description>Maximum concentration (Cmax) .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Daunorubicin Cytarabine liposomes.</measure>
    <time_frame>predose and up to 24 hours post-dose</time_frame>
    <description>Area under the concentration curve at each cycle D1 (AUC0-24).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse events</measure>
    <time_frame>up to 1 years</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 1 years</time_frame>
    <description>The number and percentage of CR and CRi in each group were calculated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Daunorubicin Cytarabine liposome for injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction 1: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (&gt;90 min) d1,3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vyxeos + Daunorubicin Cytarabine liposome for injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction 1: Vyxeos[100 U/m²] i.v. (120 min) d1; Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (&gt;90 min) d1,3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Cytarabine liposome for injection</intervention_name>
    <description>Induction 1: [100 U/m²] i.v. d1,3,5 Induction 2: [100 U/m²] i.v. d1,3</description>
    <arm_group_label>Daunorubicin Cytarabine liposome for injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vyxeos、Daunorubicin Cytarabine liposome for injection</intervention_name>
    <description>Induction 1: [100 U/m²] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: [100 U/m²] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）</description>
    <arm_group_label>Vyxeos + Daunorubicin Cytarabine liposome for injection</arm_group_label>
    <other_name>Vyxeos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient volunteers to participate in this study and sign the informed consent form.&#xD;
&#xD;
          2. Aged 55-70 years, no gender limitation.&#xD;
&#xD;
          3. Patient has a diagnosis of untreated AML according to WHO criteria.&#xD;
&#xD;
          4. Eastern Cooperation Oncology Group (ECOG) performance status of 0~1.&#xD;
&#xD;
          5. Patient has a life expectancy of 3 months or longer.&#xD;
&#xD;
          6. Patients can be followed up as required by the study.&#xD;
&#xD;
          7. Patient must meet the following criteria as indicated on the clinical laboratory tests&#xD;
             within 7 days prior to treatment :&#xD;
&#xD;
               1. White Blood Cell Count≤ 50 x 10^9;&#xD;
&#xD;
               2. Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               3. Serum total bilirubin ≤ 1.5 x ULN; ≤3 x ULN in patients with liver infiltration&#xD;
&#xD;
               4. Serum aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN;≤ 5 x&#xD;
                  ULN in patients with liver infiltration&#xD;
&#xD;
               5. Coagulation function INR or PT ≤ 1.5 x ULN; APTT ≤ 1.5 x ULN&#xD;
&#xD;
          8. Left ventricular ejection fraction ≥ 50% as assessed by echocardiography or cardiac&#xD;
             scan with multiple uptakes gated acquisition (MUGA).&#xD;
&#xD;
          9. Patients with mean value of triplicate Fridericia-corrected QT interval (QTcF) in the&#xD;
             screening period, male &lt; 450 ms, female &lt; 470 ms.&#xD;
&#xD;
         10. Female or male patients of childbearing age agree to take effective contraception&#xD;
             (such as intrauterine device [IUD], contraceptives or condoms) from the date of&#xD;
             signing an informed consent to 180 days after the last dose and female patients must&#xD;
             be non-lactating with a negative pregnancy test within 7 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has a diagnosis of acute promyelocytic leukemia (APL).&#xD;
&#xD;
          2. AML with central nervous system (CNS) involvement.&#xD;
&#xD;
          3. Patient has been previously diagnosed with another malignancy (except in the following&#xD;
             cases: Patients with cured basal or squamous cell skin cancer, superficial bladder&#xD;
             cancer, breast or cervical carcinoma in situ or focal prostate cancer with a Gleason&#xD;
             score of 6).&#xD;
&#xD;
          4. Patient with prior exposures to daunorubicin or other anthracyclines, or cytarabine.&#xD;
&#xD;
          5. The interval between any treatment medication (conventional or investigational) for&#xD;
             MDS and the first administration of this study is less than 2 weeks. However, the&#xD;
             interval between the first medication of this study and hydroxyurea which used to&#xD;
             inhibit the rapid proliferation of the tumor could be ≥ 24 hours. The study treatment&#xD;
             should be held until the toxicity be reduced to Grade 1 or below.&#xD;
&#xD;
          6. Patients who have undergone major surgery or received radiotherapy within 4 weeks&#xD;
             before the first study dose.&#xD;
&#xD;
          7. Patients who suffered from active cardiovascular diseases including but not limited&#xD;
             to: poorly controlled hypertension (ie. systolic blood pressure ≥160 mmHg and/or&#xD;
             diastolic blood pressure ≥ 90 mmHg ), myocardial infarction, unstable angina,&#xD;
             uncontrolled arrhythmia, heart failure NYHA class III/IV within 6 months before the&#xD;
             first study dose.&#xD;
&#xD;
          8. Patient has a history of severe bleeding, such as hemophilia A, hemophilia B, von&#xD;
             Willebrand disease or spontaneous bleeding that requires blood transfusion or other&#xD;
             medical intervention.&#xD;
&#xD;
          9. Patient has a history of stroke or intracranial hemorrhage within 6 months before the&#xD;
             first study dose.&#xD;
&#xD;
         10. Patient has severe lung disease within 2 weeks before the first study dose.&#xD;
&#xD;
         11. Patient has an active uncontrolled infection (acute or chronic fungal, bacterial,&#xD;
             viral or other infections).&#xD;
&#xD;
         12. Incapacity to give informed consent owe to any severe medical reasons, laboratory&#xD;
             abnormalities or mental illness .&#xD;
&#xD;
         13. Patients who have severe allergic reactions or be intolerable to liposome preparation&#xD;
             ingredients.&#xD;
&#xD;
         14. Patients with hepatolenticular degeneration or other abnormal copper metabolism.&#xD;
&#xD;
         15. Patients with positive hepatitis B surface antigen or hepatitis B core antibody with&#xD;
             hepatitis B virus DNA &gt; ULN by quantitative assay, positive hepatitis C antibody or&#xD;
             positive HIV antibody.&#xD;
&#xD;
         16. Patients who have a special diet such as grapefruit within 48 hours before the first&#xD;
             study dose.&#xD;
&#xD;
         17. Patients have received other clinical trial drugs within 28 days before screening.&#xD;
&#xD;
         18. Patients are not suitable for the study in the investigator's opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junyuan Qi, Chief doctor</last_name>
    <phone>022-23909067</phone>
    <email>qijy@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junyuan Qi, Chief doctor</last_name>
      <phone>022-23909067</phone>
      <email>qijy@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Junyuan Qi, Chief doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

